Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 13

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 13
---
 support system (DMSS) in the field of mental health, including novel diagnostics
algorithm and treatment monitoring tools allowing for true integrative care and evidence-based addiction treatment. After the closing
of the Share Exchange with LipoVation, the Company discontinued its prior activities and efforts with respect to the development and
activation of the DMSS and focused its business operations primarily on the acquired LipoVation’s business, specifically on developing
and marketing a range of novel NLP-based medicines to combat several life-threatening diseases which have no efficient treatment today.

Private Placement Offerings

Between December 2020 and August 2022, we conducted
a private placement offering (the “First Private Placement Offering”) of units of the Company’s securities, at the
price per unit of $0.80. Each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2) shares
of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s
Common Stock, exercisable for a three-year period from the date of the issuance at a per share exercise price of $0.80. We raised aggregate
gross proceeds of $2,790 thousands from the First Private Placement Offering and issued an aggregate of 6,975,000 shares of Common stock
and warrants to purchase 3,562,500 shares of Common Stock to qualified investors in this First Private Placement Offering.

In addition, between June and December 2021,
we received in escrow an aggregate of $950 thousands as subscription proceeds of a contemplated investment in the Company by certain
qualified investors and $250 thousands as subscription proceeds to an unrelated Israeli entity engaged in the treatment of addiction
and related mental disorders with whom the Company was then considering a business combination. Pursuant to the subscription agreements
executed by these investors and in accordance with their instructions and consents, the escrowed funds were released to the Company on
November 14, 2023, upon the Company’s entering into the Share Exchange Agreement, and on that date we issued to these investors
in the aggregate 3,000,000 shares of the Common stock and warrants to purchase 1,500,000 shares of our Common Stock on the same terms
as the terms of the First Private Placement Offering. In December 2023, our board decided to extend the exercise period of all of the
outstanding warrants through December 1, 2026.

<div align='center'>